Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Bone Marrow Cells in Idiopathic Dilated Cardiomyopathy
NCT02033278Phase 2Terminated
- Start
- Jan 2014
- Primary completion
- Oct 2018
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of autologous bone marrow-derived mononuclear cell in idiopathic dilated cardiomyopathy (IDC). Primary endpoint: Changes in ventricular function measured angiographically at 24 months. Started Jan 2014; status: terminated.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
idiopathic dilated cardiomyopathy (IDC)
Beyond the preview
Go deeper on NCT02033278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02033278.